Exclusive
Martin Shkreli’s former company is losing money, watching sales of its famously costly medicine slip while considering yet another name change.
Vyera Pharmaceuticals, formerly called Turing Pharmaceuticals, lost more than $1 million in the first quarter of 2018, according to financial documents obtained by STAT. Sales, driven by the $750-a-pill Daraprim, have been on the wane over the past two years, falling more than 14 percent in 2017 and on pace to drop another 7 percent in 2018.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Authors
The words “lipstick” and “pig” spring to mind…
The problem with this article is that you don’t separate R&D. This is voluntarily high and not a mandatory expense. I could be wrong but this is the company’s objective. Unlike large pharma they reinvest almost every $ to develop new and better drugs
If you believe Dave, I have a lovely Island in the Caribbean to sell you!